Teva Pharmaceutical Industries Ltd. Gets a Taste of its Own Medicine

Last week, Teva Pharmaceutical  (NYSE: TEVA  ) failed in another effort to block generic versions of its multiple sclerosis drug Copaxone from being approved by the Food and Drug Administration. The company, which also makes generic drugs, requested that a judge force the FDA to require additional tests to prove equivalency before the agency approved the copycats. The judge refused.

Copaxone is a complicated molecule made up of four different amino acids. It is hypothesized that the random chain of amino acids acts as a decoy to the immune system, decreasing the multiple sclerosis attacks.

Mylan (NASDAQ: MYL  )  is developing a generic version of the drug, as is a joint effort by Momenta Pharmaceuticals (NASDAQ: MNTA  ) and Novartis (NYSE: NVS  ) . The companies claim they've characterized the brand-name drug well enough to show their products are equivalent. By ignoring Teva Pharmaceutical's request for additional tests, the agency seems to be siding with the generic-drug makers, though it hasn't approved generic versions yet.

The potential windfall for Mylan, Momenta Pharmaceuticals, and Novartis is huge; Teva books about $4 billion in Copaxone sales annually, with most coming from the U.S.

In the video below, senior biotech specialist Brian Orelli and health-care analyst David Williamson discuss the impact on Teva, including an appeal to the Supreme Court and the potential to switch patients to a three-days-per-week version of Copaxone to fight the coming generics.

No copycats here
Let's face it, every investor wants to get in on revolutionary ideas before they hit it big. Like buying PC-maker Dell in the late 1980s, before the consumer computing boom. Or purchasing stock in e-commerce pioneer Amazon.com in the late 1990s, when it was nothing more than an upstart online bookstore. The problem is, most investors don't understand the key to investing in hyper-growth markets. The real trick is to find a small-cap "pure-play" and then watch as it grows in EXPLOSIVE lockstep with its industry. Our expert team of equity analysts has identified one stock that's poised to produce rocket-ship returns with the next $14.4 TRILLION industry. Click here to get the full story in this eye-opening report.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2965445, ~/Articles/ArticleHandler.aspx, 12/21/2014 11:02:02 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement